United Therapeutics Corporation
NASDAQ:UTHRBiotechnology
-$18.01 today
- Market cap
- $24.59B
- Beta
- 0.57
- P/E (TTM)
- 18.0
- EPS (TTM)
- $29.60
Volume 0.42M
Average 0.52M
UTHR Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
United Therapeutics CorporationNASDAQ: UTHR
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $77.3M rose 104.5% year over year, ahead of the +12.4% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +11.4% a year.
Context
- Stock-based compensation amounted to 4.6% of revenue in FY2025, down 0.4 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +104.5% holds above the trailing-twelve-month pace of +12.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 147.7M USD
- Year-over-year change
- +2.6%
- 4-year CAGR
- +1.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 147.7M | +2.6% |
| FY2024 | 2024-12-31 | 144M | +268.3% |
| FY2023 | 2023-12-31 | 39.1M | -63.4% |
| FY2022 | 2022-12-31 | 106.8M | -22.9% |
| FY2021 | 2021-12-31 | 138.5M | — |
Stock-Based Compensation vs competitors
How UTHR compares with its peers on the latest reported figures
- UTHR's LTM Jun 2026 stock-based compensation of $155.4M is the largest of the 5 companies compared; the peer median is $63.89M.
- Its year-over-year change of +12.4% is the 4th highest of 5, against a peer median of +78.4%.
- Stock-based compensation amounts to 4.9% of revenue for UTHR, versus a peer median of 11.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $155.4M | +12.4% | +11.4% | 4.9% | |
| LTM Jun 2026 | $118.44M | -11.8% | +38.3% | 10.4% | |
| LTM Sep 2026 | $72.84M | +70.9% | +5.6% | 11.2% | |
| LTM Jun 2026 | $54.95M | +126.3% | +46.9% | 12.2% | |
| LTM Mar 2026 | $18.83M | +85.9% | +222.1% | — | |
| Peer median (excluding UTHR) | $63.89M | +78.4% | +42.6% | 11.2% | |
Competitors are the stored peer set for UTHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 475.8M | 727.3M | 984.8M | 1.2B | 1.33B |
| Depreciation & Amortization | 49.9M | 51.3M | 53.2M | 72.5M | 85.6M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 97.7M |
| Stock-Based Compensation | 138.5M | 106.8M | 39.1M | 144M | 147.7M |
| Change in Working Capital | (174.2M) | (141.2M) | (97.8M) | (60.2M) | (106.4M) |
| Accounts Receivables | (41.3M) | (21.7M) | (58.5M) | (400K) | (70.9M) |
| Inventory | (7.5M) | (13.4M) | (13.6M) | (46.9M) | (52.6M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 97.9M |
| Other Working Capital | (125.4M) | (106.1M) | (25.7M) | (12.9M) | (80.9M) |
| Other Non-Cash Items | 108.2M | 58.3M | (1.3M) | (24.3M) | 2M |
| Operating Cash Flow | 598.2M | 802.5M | 978M | 1.33B | 1.56B |
| Capital Expenditures | (120.8M) | (138.8M) | (230.4M) | (246.5M) | (520.5M) |
| Acquisitions (Net) | 0 | (1.5M) | (89.2M) | (30.5M) | 0 |
| Purchases of Investments | (1.9B) | (1.71B) | (2.51B) | (1.65B) | (3.46B) |
| Sales of Investments | 1.53B | 1.03B | 2.14B | 2.37B | 1.58B |
| Other Investing Activities | 0 | 3.5M | (23M) | (28.5M) | 1.85B |
| Investing Cash Flow | (486.9M) | (811.5M) | (719.6M) | 417.2M | (551.3M) |
| Debt Repayment | 0 | 0 | (100M) | (400M) | (300M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 183.1M |
| Common Stock Repurchased | (10.8M) | (11.4M) | (13.8M) | (1.01B) | (1B) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 55.6M | 86.8M | 101.9M | 157.4M | (33.1M) |
| Financing Cash Flow | 44.8M | 75.4M | (11.9M) | (1.25B) | (1.15B) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 156.1M | 66.4M | 246.5M | 489.5M | (140.1M) |
| Free Cash Flow | 477.4M | 663.7M | 747.6M | 1.08B | 1.04B |
United Therapeutics Corporation
NASDAQ:UTHR
Intrinsic Alpha fair value
Locked
Current Price
$577.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.